Online inquiry

IVTScrip™ mRNA-Human ACTR3C, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK10674MR)

This product GTTS-WK10674MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ACTR3C protein. This product can be used in Regulatory T (Treg) cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001164458.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 653857
UniProt ID Q9C0K3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ACTR3C, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK10674MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK19637MR IVTScrip™ mRNA-Human alpha-SMA, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA alpha-SMA
GTTS-WK24379MR IVTScrip™ mRNA-Human ARGLU1, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARGLU1
GTTS-WK8988MR IVTScrip™ mRNA-Human AGAP2, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGAP2
GTTS-WK21213MR IVTScrip™ mRNA-Human ANKRD27, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANKRD27
GTTS-WK23812MR IVTScrip™ mRNA-Human ARHGEF19, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARHGEF19
GTTS-WK20964MR IVTScrip™ mRNA-Human ANXA6, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ANXA6
GTTS-WK23110MR IVTScrip™ mRNA-Human APIP, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APIP
GTTS-WK1899MR IVTScrip™ mRNA-Human CD59, (Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CD59
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW